drugset / Trial / NCT03410043
Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study
Phase 2
Active not recruiting
173 enrolled
M.D. Anderson Cancer Center
National Cancer Institute (NCI) · collabNational Comprehensive Cancer Network · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This phase II trial studies how well osimertinib, surgery, and radiation therapy work in treating patients with stage IIIB or IV non-small cell lung cancer with EGFR mutations. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving osimertinib, surgery, and radiation therapy may work better at treating non-small cell lung cancer with EGFR mutations.
Timeline
- Start
- 2018-01-17
- Primary completion
- 2027-04-01
- Completion
- 2027-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Osimertinib | Small molecule | — | Oral |